Back to top

biotechnology: Archive

Andrew Rocco

Biotech: 3 Profitable Bios Worth Owning

The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects.

GILDPositive Net Change MRNANegative Net Change CPRXPositive Net Change

Zacks Equity Research

Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy

Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

GILDPositive Net Change IMGNPositive Net Change JNCEPositive Net Change ACLXNegative Net Change

Zacks Equity Research

3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023

Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.

GSKPositive Net Change PCRXNegative Net Change GLPGNegative Net Change VIRNegative Net Change

Zacks Equity Research

Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals

Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.

GSKPositive Net Change GILDPositive Net Change SNDXPositive Net Change IMCRNegative Net Change

Zacks Equity Research

Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day

Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.

MLABPositive Net Change EGOPositive Net Change ADAPNegative Net Change KMDANegative Net Change ZYMENegative Net Change

Zacks Equity Research

4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.

GILDPositive Net Change GSKPositive Net Change SNDXPositive Net Change IMCRNegative Net Change

Sundeep Ganoria

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

ADAPNegative Net Change KMDANegative Net Change ZYMENegative Net Change

Zacks Equity Research

Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment

Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.

GSKPositive Net Change JNJPositive Net Change GILDPositive Net Change

Andrew Rocco

Biotech is Set for a Blockbuster 2023: Here's Why

The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?

MRKPositive Net Change GILDPositive Net Change MRNANegative Net Change IBBNegative Net Change QQQNegative Net Change SPYNegative Net Change XBINegative Net Change

Ekta Bagri

Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More

Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.

GILDPositive Net Change MDGLPositive Net Change RCUSNegative Net Change TRDANegative Net Change

Ekta Bagri

3 Drug Stocks Most Wall Street Analysts Are Bullish About

Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

LLYPositive Net Change UTHRNegative Net Change IMCRNegative Net Change

Zacks Equity Research

Entrada (TRDA) Down on Regulatory Update for DMD Candidate

Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate.

GILDPositive Net Change VRTXNegative Net Change KPositive Net Change KALAPositive Net Change TRDANegative Net Change

Zacks Equity Research

bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA

bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.

GILDPositive Net Change KALAPositive Net Change IMCRNegative Net Change

Zacks Equity Research

Stock Market News for Dec 19, 2022

U.S. stock markets closed sharply lower On Friday as market participants remained concerned about a recession in 2023.

MRNANegative Net Change

Zacks Equity Research

BioCryst (BCRX) Down as it Discontinues Developing PNH Drug

BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.

BCRXNegative Net Change GILDPositive Net Change VTGNPositive Net Change VIRNegative Net Change

Zacks Equity Research

Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting

Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.

AMGNPositive Net Change GILDPositive Net Change CYTKNegative Net Change VTGNPositive Net Change

Debdutta Sinha

5 Momentum Stock Bargains Hunters Would Love Chasing

Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.

SNYNegative Net Change GSKPositive Net Change UALNegative Net Change UTHRNegative Net Change ULTANegative Net Change

Nalak Das

Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left

we have identified five non-technology Nasdaq stocks that have popped in 2022 despite the index's blood bath. These are: UTHR, LPLA, ENPH, SWAV, CHX.

UTHRNegative Net Change LPLANegative Net Change ENPHPositive Net Change SWAVPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More

Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.

AMGNPositive Net Change GILDPositive Net Change VRTXNegative Net Change HZNPPositive Net Change TRDANegative Net Change